glp 1 drug classification GLP-1 Comparison in Diabetes and Obesity Treatment Market Overview: GLP-1 Agonists and
Description
Buckley STSS, Kirk RK, Knudsen LB
A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity
This matters more in older adults, in anyone whose function depends on strength, and in anyone with low muscle reserve to start with
43,44 Given these neutral-to-concerning results, there is currently no evidence to support initiating GLP-1RAs for the primary treatment of HFrEF
Highlights of Prescribing Information: BYETTA (exenatide) injection, for subcutaneous use
